Biohit Oyj
Sector unknown·BIOBV · Nasdaq Helsinki·Fiscal year to 31/12/2025
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Healthcare and hospitals
End markets
DriverPositive impact: strengthens
“Healthcare systems are visibly under strain. The need for more efficient allocation of scarce healthcare resources is global. The Homerton study clearly increased interest in a product that directly addresses this need.”
Annual report 2025A · The company itself
StrategyPositive impact: strengthens
“Our objective is clear: to have GastroPanel ® included in the national treatment guidelines of as many countries as possible.”
Annual report 2025A · The company itself
Market
“The GastroPanel ® quick test saves costs and unnecessary visits to the clinic, enabling endoscopic examinations to be targeted at patients who need them most urgently. Patient safety is improved as follow-up examinations, treatment, and monitoring are accelerated.”
Annual report 2025A · The company itself
Market
“Its use in clinical practice will produce a substantial financial and environmental impact by avoiding unnecessary upper GI endoscopy procedures and help keep the focus on patients with high-risk precancerous lesions.”
Annual report 2025A · The company itself
Chains in: Ageing population strengthens, GLP-1 and obesity treatment mixed effect
Medical devices
Technology
Market
“Corporate Governance Statement 2025 11 Information for Shareholders 17 Board of Directors 18 Group Management Team 20 Financial Statements 21 Biohit in Brief Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products.”
Annual report 2025A · The company itself
Market
“Sales of rapid tests increased by 28.7% compared with the previous year.”
Annual report 2025A · The company itself
Market
“Growing Momentum for GastroPanel ® Biohit’s flagship product and most important growth driver is GastroPanel ® . Its value proposition is clear: GastroPanel ® enables accurate and reliable diagnosis of upper gastrointestinal symptoms in primary healthcare.”
Annual report 2025A · The company itself
Chains in: Ageing population strengthens
Biotech and drug development
Technology
Market
“Corporate Governance Statement 2025 11 Information for Shareholders 17 Board of Directors 18 Group Management Team 20 Financial Statements 21 Biohit in Brief Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products.”
Annual report 2025A · The company itself
Chains in: US drug pricing policy mixed effect, Patent expiry and generic competition weakens, Drug approvals strengthens
Chains out: this strengthens Buying contract manufacturing and research (CMO/CRO/EMS), strengthens Contract manufacturers as a business (EMS, CMO, CRO)
Tobacco regulation and excise
Regulation
Market
“lozenges are an innovation from Biohit that help you quit smoking by binding acetaldehyde in saliva with L-cysteine.”
Annual report 2025A · The company itself
Geopolitical uncertainty
Macro
DriverNegative impact: weakens
“During the first half of the year, escalation in the Middle East kept us on the starting blocks, and revenue increased by only 0.3% compared with the reference period. In the second half of the year, the pace accelerated and growth reached 20.7% year-on-year. Deliveries interrupted in the Middle East were resumed, although volumes remained at only half of previous levels.”
Annual report 2025A · The company itself
Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine
Ageing population
Geography
DriverPositive impact: strengthens
“Global problems - Global solutions Widening markets • Presence in all relevant markets • Europe, Asia, South America, North America Widening product portfolio • Sustainable high-quality offering • Dynamic portfolio management • Partnerships Active sales • Market driven sales • Need - Solution - Value-add • Closer to the customer Attractive for talents and investors • Profitable growing healthtech • Active talent acquisition • Active investor policy Ageing population Increasing gastrointestinal problems Scarce health care resources Annual growth 15-20% EBIT min 10% Vision: Gastrointestinal tract premium expert • Combining the business and the science • Innovations and collaborations • Premium brand • R&D Innovative Products GastroPanel ® quick test NT A unique innovation for monitoring stomach health The GastroPanel ® quick test assesses the structure and function of the stomach lining.”
Annual report 2025A · The company itself
Chains out: this strengthens Healthcare and hospitals, strengthens Medical devices, strengthens Hearing aids and hearing care
Asia and emerging markets
Geography
Geography
“The regional focus remained in Asia, but sales have also developed positively elsewhere.”
Annual report 2025A · The company itself
Europe
Geography
Geography
“It was decided to close the Italian subsidiary and, going forward, to cover the Italian market through a more cost-efficient distributor model. The better-scalable UK subsidiary will continue to operate unchanged.”
Annual report 2025A · The company itself
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.02 bn EUR |
| Revenue growth vs. the year before, same method | 10.1 % |
| EBITDA reported by the company | N/A |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | 18 EUR |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✓ |
| Growing | ✓ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (EUR), not converted to DKK. Quotes are shown as the company's own words in the report's original language.